In a clinical study, thirty-one patients diagnosed with heart failure with preserved ejection fraction and CRP (C-reactive protein) levels > 2 mg/L were randomly assigned to receive either anakinra (a recombinant IL-1 receptor antagonist) at a daily subcutaneous dose of 100 mg (N = 21) or a placebo (N = 10) for a duration of 12 weeks. This evidence concerns the gene CRP and heart failure.